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Summary
INTRODUCTION: Delirium has been recognised as an
underdiagnosed and undermanaged syndrome with sub-
stantial prevalence rates and potentially deleterious con-
sequences in the medically ill population. Despite its fre-
quent administration in the management of delirium, the
effectiveness of pipamperone has not yet been evaluated.
METHODS: In this retrospective, descriptive cohort study
of 192 patients, pipamperone as monotherapy and as an
adjunct to haloperidol, haloperidol alone, or atypical an-
tipsychotics were compared with respect to their effective-
ness in the management of delirium and its subtypes over
the course of 20 days.
RESULTS: In this elderly patient population, pipamperone
alone and as an adjunct to haloperidol was as effective
as haloperidol or atypical antipsychotics in the manage-
ment of delirium. Management with low-dose pipamper-
one monotherapy achieved delirium resolution in 70% of
patients, over a mean of 6.4 (2–20) days. With pipam-
perone as an adjunct to haloperidol, delirium resolved in
59% of patients, over a mean of 7.4 (2–20) days. When
haloperidol or atypical antipsychotics (risperidone, olan-
zapine or quetiapine) were used, the delirium resolution
rates were 72 and 67%, over a mean of 5.2 (2–11) and 6.4
(2–20) days, respectively. The addition of pipamperone to
haloperidol decreased the requirement for lorazepam. Pi-
pamperone proved to be equally effective in all delirium
subtypes – hypoactive, hyperactive and mixed. Nonethe-
less, potential bias could not be excluded in this observa-
tional design.
CONCLUSION: From these initial results, low-dose pi-
pamperone was as effective as haloperidol or atypical an-
tipsychotics in the management of delirium and its sub-
types, and was benzodiazepine-sparing when used as an
adjunct to haloperidol.
Key words: haloperidol, pipamperone, antipsychotics,
delirium, subtypes, effectiveness
Introduction
Delirium is a neuropsychiatric syndrome characterised by
an abrupt onset and fluctuating disturbances in conscious-
ness and cognition, as well as a range of noncognitive
domains including disturbances in motor behaviour, emo-
tionality and sleep-wake cycle, caused by an underlying
aetiology [1, 2].
Delirium is a common occurrence over the course of hos-
pitalisation, depending, among other factors, on the age
and gender of the patient, previous episodes of delirium,
pre-existing dementia and severity of illness [3–5]. Across
the hospital, including the medical, surgical or general set-
tings, delirium rates vary between 10 and 60% [5] and in
the intensive care setting varies between 60 and 82% [4–7].
If not managed appropriately, delirium can exert a very ad-
verse effect on clinical outcomes. This can include short-
term consequences such as increased morbidity and mor-
tality, and prolonged hospitalisation, as well as long-term
consequences such as increased rates of cognitive decline,
deterioration in functionality and institutionalisation [8,
9]. Another factor contributing to worsened delirium out-
comes has been identified as delirium severity, with more
severe episodes associated with worse outcomes [10, 11].
In particular, persistent delirium has been recognised to
predict worse outcomes. Such persistence of delirium has
been documented as long as 3 and 6 months after hospital
discharge, leading to the conclusion that delirium may be
much less transient than previously assumed [12–14]. Per-
sistent delirium is also associated with a greater risk of
death [15, 16]. In contrast, delirium symptoms resolving
within 2 weeks have been associated with excellent func-
tional recovery [12], and resolved delirium with decreased
mortality [15].
As a result of its different psychomotor representations,
delirium has been further characterised into hypoactive,
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hyperactive and mixed subtypes. The hypoactive subtype
is characterised by decreased activity, apathy, decreased
speed of activity and speech, decreased volume of speech,
decreased alertness, and withdrawal; the hyperactive sub-
type by increased activity, loss of control of activity, rest-
lessness, and wandering; and the mixed subtype by the
occurrence of both hypoactive and hyperactive features
within a given day [17].
Due to its adverse short- and long-term consequences [8,
9], delirium prevention strategies [18, 19] and, once detect-
ed, management strategies have been devised. The man-
agement approach to delirium relies on eliminating the un-
derlying aetiology, providing environmental interventions
like hearing and visual aids, frequent reorientation and, if
necessary, pharmacological management [2]. Haloperidol
remains the gold standard [2],but an increasing number of
studies are supporting the administration of other, atypical
antipsychotics. Altogether, delirium studies indicate remis-
sion rates from 40 to 90% [20, 21].
Pipamperone, a low potency antipsychotic and an antago-
nist of 5HT2A-C-, D2-4- and α1-2-receptors with much higher
activity against the D4 and 5HT2A than D2 receptor and in-
significant activity against histamine1 and muscarinic-an-
ticholinergic (mACh) receptors [22], is recommended for
the management of delirium [23, 24]. However, to date the
effectiveness of pipamperone for this purpose has not yet
been evaluated at all. Thus, in this study, the effectiveness
of pipamperone alone and as an adjunct to haloperidol was
compared with that of haloperidol alone, as well as atypical
antipsychotics, in the management of delirium, both over-
all and its various clinical subtypes.
The aim of this study was to assess the effectiveness of pi-
pamperone alone and as an adjunct to haloperidol in the
management of delirium versus the gold standard haloperi-
dol or atypical antipsychotics such as risperidone, olanza-
pine and quetiapine.
Methods
This study was approved by the ethics committee of the
Canton of Zurich (KEK-ZH-Nr. 2012-0263).
Patients and procedures
All patients in this retrospective, descriptive cohort study
were recruited at the University Hospital Zurich during
an ongoing evaluation using the Delirium Observation
Screening scale (DOS) three times daily over the first three
days, in addition to initiating screening on suspicion of in-
cident delirium. The DOS scoring was performed by nurs-
ing staff specifically trained in use of the DOS via video
training material and subsequent discussion and agree-
ment. Once the DOS indicated delirium, the short version
of the Confusion Assessment Method (S-CAM) was ad-
ministered by nursing staff specifically trained in the use
of this scales via a mandatory training programme.
Delirium management schedule
Once the diagnosis was established, the delirium manage-
ment schedule was initiated and DOS scoring continued
three times daily for as long as delirium was considered
present.
This schedule differentiated between hypoactive and hy-
peractive or mixed delirium. The mainstay of management
of hypoactive delirium was haloperidol, starting with a
dose of 0.5 to 2 mg and increasing to a maximum of 10 mg
daily, plus pipamperone 20 mg up to a maximum of 80 mg
daily in those patients with anxiety, distress or restlessness.
The mainstay of management of the hyperactive and mixed
subtypes was pipamperone, starting at 20 to 40 mg, in-
creasing up to a maximum of 80 mg daily. When delusions
or perceptual disturbances were present, haloperidol was
initiated at 0.5 to 2 mg, up to a maximum of 10 mg daily.
When agitation occurred, lorazepam 0.5 to 2.5 mg, up to
a daily maximum dose of 7.5 mg, was added throughout
the daytime and at night. Haloperidol was administered
throughout the day, whereas the focus of pipamperone ad-
ministration was the night-time in order to reinforce or
restore the sleep-wake cycle pattern. Once clinical im-
provement was evident, the delirium management sched-
ule recommended reducing the doses of administered med-
ications by 50%.
In addition, patients were also managed with risperidone,
olanzapine and quetiapine for delirium.
In total, 192 patients were retrospectively enrolled. Inclu-
sion criteria were the presence of delirium, active man-
agement of delirium with psychotropic medication, and
DOS recordings for more than three days. Exclusion crite-
ria were the absence of delirium, an insufficient duration
of DOS recordings, and transfer to other facilities shortly
after initiation of the delirium management schedule.
Once patients were included in this study, sociodemo-
graphic variables like age and gender, medical or surgical
variables, as well as psychiatric diagnoses were collected.
These psychiatric diagnoses were classified as cognitive
disorders including dementias, addictive, psychotic and af-
fective disorders, or other. Among management variables,
psychotropic medications administered were recorded in
daily doses, including all psychotropic medications in the
delirium management protocol, as well as other antipsy-
chotics and lorazepam.
Because of the nature of the protocol, various combina-
tions of medications were possible. For the purposes of
analysis, these were grouped into four categories: (1) pi-
pamperone monotherapy; (2) pipamperone as an adjunct
to haloperidol; (3) haloperidol alone accepted as the gold
standard; and (4) atypical antipsychotics, including risperi-
done, olanzapine and quetiapine, accepted as viable alter-
natives to haloperidol.
Remission of delirium was defined as scores of less than
7 on three DOS measurements within 24 hours. Subtyping
of delirium was based on DOS items 10, 11, and 13, a val-
idated and reliable approach [25, 26].
Measurements
Delirium rating scales implemented in this study were the
Delirium Observation Screening Scale (DOS) and the short
version of the Confusion Assessment Method (S-CAM).
The DOS has been validated in the screening of delirium
and measurement of delirium severity [25, 26]. The scale
reflects the Diagnostic and Statistical Manual of Mental
Disorders fourth edition (DSM-IV) criteria of delirium and
was designed to capture early delirium symptoms. The
DOS has 13 items, each with a three-point rating scale
(0–2), with rating possibilities of not existent, sometimes
to always, and unable to assess. These items reflect distur-
bances in the patient’s level of consciousness [1], attention
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[2–4], thought processes [5, 6], orientation [7, 8], memory
[9], psychomotor behaviour [10, 11, 13], and affect [12]. A
total score of three or more indicates delirium.
The short version of the S-CAM [27] is a diagnostic tool
validated for the assessment of delirium, reflecting the
DSM III-R criteria for delirium. Items include: (1) an
abrupt change in mental status; sub-items (2A) a distur-
bance in attention; (2B) a fluctuating course; and (2C) any
inattention observed; (3) altered thought processes; and
(4) depressed level of consciousness. Available ratings for
items 1, 2B, 2C and 3 are yes, no, uncertain and not ap-
plicable; for sub-item 2A, not present, present in a mild
form, present in a marked form, or uncertain; and for item
4, alert, hypervigilant, lethargic, stuporous, comatose, or
uncertain. The diagnosis of delirium requires (1) an acute
onset and fluctuating course; as well as (2) inattention and
either (3) disorganised thinking or (4) an altered level of
consciousness.
Statistical methods
Data analyses were performed with the Statistical Package
for the Social Sciences (SPSS) version 22 and Stata/SE
13.1 for Windows. Characteristics of the sample were sum-
marised as mean with standard deviation for continuous
variables like age, median with interquartile range for con-
tinuous variables where the distribution was skewed, and
percentages for categorical variables like gender. Inter-
group differences for continuous variables were identified
by analysis of variance (ANOVA), in those instances in
which the distribution of the data was skewed like dosing
of medications, the nonparametric Kruskal-Wallis H-test,
and for categorical variables by Pearson’s χ2 test.
To evaluate differences in medication administration be-
tween haloperidol and pipamperone as an adjunct to
haloperidol, the Mann-Whitney U-test for independent
variables was computed. To detect differences in the effec-
tiveness of delirium management between the four med-
ication subgroups (pipamperone alone; pipamperone as an
adjunct to haloperidol; haloperidol alone; and other atyp-
ical antipsychotics), a Cox-regression model was created
from the time to event, with the event set as the remission
of delirium. When age and baseline delirium severity were
different between the groups, these variables were included
as covariates. The contrast was set on medications used
and the indicator on pipamperone. The validity of the pro-
portional hazard assumption in the Cox model was tested
with Schoenfeld residuals (global test: χ2 = 1.26, p = 0.74;
medication subgroups: ρ = 0.06, p = 0.47). For the three
subtypes of delirium, a similar Cox-regression model was
created with the indicator set on hypoactive delirium. The
validity of the proportional hazard assumption in this Cox
model was tested with Schoenfeld residuals (subtypes: ρ =
˗0.03, p = 0.72). Since the ‘event’ for the Cox-regression
model was remission from delirium, the survival function
represented the remission function and the hazard function
represented the benefit function.
For all inferential tests, the significance level alpha (α) was
set at p <0.05, and all tests were two-tailed.
Results
Baseline and management characteristics of the pa-
tient sample
The patient population included elderly, predominantly
male patients from various medical and surgical referrals
(table 1). More common psychiatric diagnoses included
cognitive, addictive and affective disorders. The initial
DOS scores indicated substantial impairment and the cu-
mulative DOS scores reached 100.
On average, modest amounts of pipamperone were admin-
istered, in contrast to the high maximum doses admin-
istered to some patients. The average dose of pipamper-
one was 421 mg, with cumulative doses of between 10
and 2520 mg administered over the course of management.
With respect to haloperidol, mean doses were 13 mg, and
maximum doses reached 92 mg. Corresponding doses for
lorazepam were 8 and 155 mg. In two thirds of patients, re-
mission of delirium was recorded, the mean time to remis-
sion being the sixth day of management.
Baseline and management characteristics of the four
medication groups
Medication group differences in sociodemographic, med-
ical, psychiatric and management variables were few (table
1). Patients in the haloperidol-alone group were younger
(65.7 years) than those in any other group.
The gender distribution was equal across the groups, with
male patients accounting for two thirds of the overall sam-
ple. Cognitive disorders were equally distributed between
medication groups. In contrast, in those patients managed
with pipamperone alone and as an adjunct to haloperidol,
the prevalence of addictive disorders was lower.
At baseline, the DOS scores of the pipamperone-managed
patients were lower. Altogether, modest doses of pipam-
perone, haloperidol, and atypical antipsychotics sufficed
for the management of delirium.
Pipamperone alone or as an adjunct to haloperidol
When pipamperone alone was the mainstay of delirium
management, an average cumulative dose of 401 mg was
administered, with individual daily doses ranging from 5
to 320 mg to achieve a remission rate of 70%, on average
on the sixth day of management. When pipamperone was
used as an adjunct to haloperidol, comparable cumulative
doses of pipamperone (463 mg) were administered, the
daily range being from 10 to 320 mg. In this group, the
delirium resolution rate was 58.7%, with resolution oc-
curring, on average, on day 7. Daily doses of haloperidol
ranged from 0.5 to 18 mg. Among all the medication
groups, lorazepam was administered in the lowest dose
in this group. In particular, much less lorazepam than
haloperidol was required (4 vs 26 mg, Mann-Whitney U-
test p = 0.023).
Haloperidol
When haloperidol was administered alone, the average
dose was 17.7 mg, and this resulted in more than a 70%
rate of remission, which occurred, on average, on day 5.
Daily doses ranged from 0.5 to 13 mg. Relative to manage-
ment with pipamperone alone or as an adjunct to haloperi-
dol, or atypical antipsychotics, higher doses of lorazepam
were required to achieve symptom control in this group.
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Atypical antipsychotics
When atypical antipsychotics were the mainstay of man-
agement, on average 7 mg of risperidone, 65 mg of olan-
zapine, or 850 mg of quetiapine were administered daily.
In this medication group, remission was achieved in nearly
60%, on average on day 6.
Effectiveness of pipamperone alone or as an adjunct to
haloperidol versus haloperidol alone or atypical an-
tipsychotics
The management of delirium with pipamperone alone and
as an adjunct to haloperidol proved to be equally effective
as management with haloperidol alone or atypical antipsy-
chotics. The omnibus test of model coefficients was sig-
nificant with respect to pipamperone alone and as an ad-
junct to haloperidol versus haloperidol and atypical an-
tipsychotics (p <0.001). Between pipamperone alone or as
adjunct to haloperidol, haloperidol alone or atypical an-
tipsychotics, neither the time to remission nor the hazard
ratio, which represents a benefit ratio, were different (table
2, figs 1 and 2). However, there was a trend toward lower
efficacy when pipamperone was used as an adjunct to
haloperidol. Whether this trend was caused by lower dos-
ing of haloperidol, the severity of illness or delirium, or
some independent effect could not be determined. Both age
Table 1: Sociodemographic, medical, psychiatric and management variables of pipamperone alone, as an adjunct to haloperidol in comparison, haloperidol and atypical antipsy-
chotics.
All patients
(n = 192)
Pipamperone
(n = 91)
Haloperidol and pi-
pamperone
(n = 46)
Haloperidol
(n = 25)
Atypical antipsychotics
(n = 30)
p-value
Age in years* 72.1
(27.9–95.2, 13.5)
74.4
(39.1–95.1, 10.7)
72.8
(39.3–90.4, 11.9)
65.7
(29.2–87.3, 17.1)
68.2
(27.9–95.2, 17.9)
0.008†
Gender in %
Male 63.5 69.2 60.9 64 50
Female 36.5 30.8 39.1 36 50
0.286‡
Referral from, in %
Cardiology 29.2 46.2 28.3 4 –
Medicine 16.7 12.1 19.6 24 20
Neurology 21.4 20.9 13 8 46.7
Oncology 15.6 12.1 26.1 20 6.7
Surgery 8.9 2.2 8.7 24 16.7
Traumatology 5.2 6.6 2.2 4 6.7
Other 3.1 – 2.2 16 –
0.593‡
Psychiatric disorders, in %
Cognitive 14.6 14.2 13 12 20 0.827‡
Addictive 13 7.7 8.7 28 23.3 0.011‡
Psychotic 3.1 – – 8 13.3 0.001‡
Affective 10.9 6.6 10.9 20 16.7 0.183‡
Other 4.7 2.2 4.3 4 13.3 0.097‡
DOS scores – initial 24
hours*
15.3
(1–39, 7.2)
13.7
(1–33, 7)
16.4
(6–39, 7.4)
17.8
(6–33, 7.2)
17.8
(6–33, 7.2)
0.030†
DOS scores – cumulative* 90.7
(8–485, 76.6)
83.1
(8–458, 77.1)
118.3
(22–371, 81.4)
73.8
(17–224, 52.8)
85.4
(9–342, 77.2)
0.041†
Pharmacological manage-
ment with**
Haloperidol 12.9
(0.5–92, 14.5)
(4.3, 13.6)
0.7
(0.5–1, 0.27)
(0.5, 0.38)
12.5
(2–92, 15.3)
(7.5, 14.5)
17.7
(2–58, 13.6)
(15, 15)
1.5
(1–2, 0.7)
(1.5, –)
<0.001§
Pipamperone 421.7
(10–2520, 355) (445,
305)
401.1
(20–2520, 366.3)
(210, 242.5)
462.5
(10–1840, 331.7)
(465, 305)
– –
Atypical antipsychotic
Risperidone 19.3
(3–41, 15.4)
(11.8, 30.3)
– – 32 (32) 7.1
(1–406, 9.8)
(11, 33)
Olanzapine 57.5
(10–187.5, 66.3)
(31.3, 133.8)
– – – 65
(10–187.5, 82.3)
(31, 133.8)
Quetiapine 823.6
(75–3300, 946.7)
(350, 3225)
– – 125 (125) 856.9
(75–3,300, 956.8)
(400, 1197)
Lorazepam 8.4
(0.5–155, 18.5)
(2, 4)
6.3
(0.5–34, 7.3)
(3, 6.6)
25.8
(1–155, 44.6)
(10.5, 20)
7.1
(1–40, 9.8)
(3.8, 5)
0.056§
Remission of delirium, in % 67.2 70.3 58.7 72 66.7 0.547‡
Day of remission** 6.3
(2–20, 3.9)
(5, 5)
6
(2–20, 4.1)
(4.5, 5)
7.4
(2–20, 3.9)
(7, 5)
5.2
(2–11, 2.5)
(4, 3)
6.4
(2–20, 4.3)
(6, 5)
0.103†
DOS = Delirium Observation Screening scale * mean (range, standard deviation); ** mean (range, standard deviation (median, interquartile range) † ANOVA; ‡ Pearson’s chi-
square; § Kruskal Wallis H-test
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and delirium severity, measured DOS scores at baseline,
affected the course of delirium and time to remission.
Pipamperone for the management of the delirium sub-
types: hypoactive, hyperactive, and mixed
Baseline characteristics between the delirium subtypes
The proportion of patients with each of the three different
subtypes of delirium, among those managed with pipam-
perone, was 41.8% for hypoactive, 12.1% for hyperactive,
and 46.2% for mixed. Comparing patients with the three
subtypes, distributions for age, gender, referral service, and
psychiatric diagnoses were similar (table 3).
Delirium severity, measured as the initial DOS score, was
similar between the subtypes, and the cumulative DOS
scores – indicating the length and severity of delirium –
were comparable.
Management characteristics between the delirium sub-
types
Pharmacological therapy included pipamperone, as well as
adjunctive haloperidol and lorazepam. The cumulative pi-
pamperone dose ranged from 310 to 435 mg, with maxi-
mum doses reaching 1560 mg for the mixed and 2520 mg
for the hypoactive subtype. Haloperidol was administered
at minimal doses, ranging from 0.5 to 0.8 mg, to a maxi-
mum of 1 mg. Lorazepam was administered at doses rang-
Table 2: Variables in the equation, pipamperone alone and as an adjunct to haloperidol in the management of delirium and pipamperone in the management of its subtypes.
B SE Wald df p-value Hazard ratio 95.0% CI for hazard
ratio
Medication
Pipamperone 5.173 3 0.160 1
Haloperidol 0.267 0.277 0.927 1 0.336 1.306 0.758–2.250
Haloperidol and pipamperone ˗0.399 0.232 2.952 1 0.086 0.671 0.425–1.058
Atypical antipsychotics ˗0.0089 0.266 0.111 1 0.739 0.915 0.544–1.541
Baseline DOS scores ˗0.059 0.014 17.830 1 0.000 0.943 0.918–0.969
Pipamperone alone and as ad-
junct to haloperidol versus
haloperidol and atypical an-
tipsychotics
Age ˗0.014 0.006 4.620 1 0.032 0.986 0.974–0.999
Subtype of delirium
Hypoactive 1.325 2 0.516 1
Hyperactive 0.160 0.426 0.140 1 0.708 1.173 0.509–2.706
Pipamperone in the manage-
ment of the delirium subtypes
Mixed ˗0.246 0.266 0.851 1 0.356 0.782 0.464–1.318
B = coefficient for the constant/intercept; CI = confidence interval; df = degrees of freedom; DOS = Delirium Observation Screening scale; SE = standard error; Wald = χ2
Figure 1: Survival (remission) function of pipamperone, alone and as an adjunct to haloperidol versus haloperidol and atypical antipsychotics.
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ing from approximately 4 to 8 mg. Altogether, the doses of
pipamperone, haloperidol and lorazepam did not vary be-
tween the three subtypes of delirium.
The remission rates for delirium (as a measure of efficacy)
ranged from 64 to 76% and the time to remission from ap-
proximately 4 to 7 days. Neither measure revealed differ-
ences in the management of the three subtypes of delirium.
The omnibus test of model coefficients was not significant
for the assessment of pipamperone in the management of
the subtypes of delirium (p = 0.51). Pipamperone was
therefore equally effective in the three delirium subtypes,
as indicated by similar times to remission and hazard/ben-
efit functions.
Discussion
In this first study on the effectiveness of pipamperone in
the management of delirium, pipamperone alone and as
an adjunct to haloperidol appeared to be as effective as
haloperidol and atypical antipsychotics like risperidone,
olanzapine or quetiapine. Moreover, the adjunctive use of
pipamperone reduced the dose of lorazepam needed com-
pared with haloperidol-alone patients, thereby potentially
representing a lorazepam-sparing approach. The effective-
ness of pipamperone also did not seem to be affected by
the subtype of delirium, whether hypoactive, hyperactive
or mixed.
Comparisons to existing literature
Effectiveness of pipamperone in the management of
delirium
In the current literature on antipsychotics in patients with
delirium, delirium remission rates as measured with vari-
ous delirium rating scales generally over the course of 1
week are between 40 and 90% [20, 21]. Haloperidol seems
to be no more or less effective than atypical antipsychotics.
One limitation of the existing literature is that most stud-
ies were open-label, included just a small sample of pa-
tients and did not distinguish between the various subtypes
of delirium. Thus, differences in the effectiveness of an-
tipsychotics in managing the different subtypes of delirium
remain understudied [20, 21].
Although pipamperone is recommended as a standard ap-
proach to the management of delirium [23, 24], to date no
published studies have evaluated its effectiveness. In this
initial glimpse at pipamperone as a management for pa-
tients with delirium, it appeared to be no less effective an
option than other more established drugs, as evidenced by
similar rates of and times to remission. However, a trend
towards lower effectiveness of pipamperone when used as
an adjunct to haloperidol was noted. Whether this trend
was caused by use of lower doses of haloperidol, more se-
vere delirium (which was factored into the statistical mod-
el), or further undetermined confounding effects, warrants
further study.
Figure 2: Hazard (benefit) function of pipamperone, alone and as an adjunct to haloperidol versus haloperidol and atypical antipsychotics.
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Within the various medication groups, the administration
of pipamperone alone resulted in remission on day 6, on
average, which was similar to that achieved with haloperi-
dol alone, haloperidol and pipamperone used together, and
the atypical antipsychotics, for which the average time to
remission ranged from 4 to 6 days. Adding pipamperone to
haloperidol, though no superior to either drug used alone
in terms of overall effectiveness, did substantially lower
the dose of lorazepam needed relative to haloperidol used
alone. Adding pipamperone to haloperidol might be an
alternative, benzodiazepine-sparing approach, decreasing
their delirogenic load [28, 29].
The remission rate in the pipamperone-managed patients
was 70.3%, which was not only similar to the 59 to 72%
rates achieved with haloperidol alone, haloperidol plus pi-
pamperone, and atypical antipsychotics, but also compara-
ble to remission rates reported in the literature [20, 21].
Effectiveness of pipamperone in the management of the
subtypes of delirium
Studies exploring the effectiveness of antipsychotics for
patients with the various subtypes of delirium remain
scarce. Moreover, the existing literature presents inconsis-
tent results. For example, whereas haloperidol and risperi-
done have been found to be equally efficacious [30, 31],
aripiprazole and olanzapine may be more effective for the
hypoactive and hyperactive subtypes, respectively [32,
33]. These results suggest that pipamperone may be equal-
ly effective, irrespective of the subtype of delirium – hy-
poactive, hyperactive, or mixed – being managed.
Potential confounding effects
Although the implemented statistical models were de-
signed to control for confounding effects [34], some of
these effects need to be mentioned. The delirium manage-
ment schedule determined the medication chosen, although
variations occurred. Hypoactive delirium was primarily
managed with haloperidol in the presence of perceptual
disturbances. Delirium in those managed with pipamper-
one was marginally milder. The impact of underlying dis-
eases or type of delirium between pipamperone used alone
or as an adjunct to haloperidol versus haloperidol alone or
antipsychotics could not be determined. Further, although
not reaching significance, the referring specialties and co-
morbid psychiatric disorders varied between management
groups. Whether these differences affected the manage-
ment outcome is not known and could not be determined.
Table 3: Sociodemographic, medical, psychiatric and management variables of pipamperone in the subtypes of delirium hypoactive, hyperactive and mixed delirium.
Hypoactive delirium
(n = 38)
Hyperactive delirium
(n = 11)
Mixed delirium
(n = 42)
p-value
Age in years* 76.
(39.1–90.6, 9.8)
71.1
(41.7–85.3, 11.8)
73.9
(50.2–95.1, 11)
Gender in %
Male 71.1 63.6 69 0.247†
Female 28.9 36.4 31 0.949‡
Referral from, in %
Cardiology 47.4 72.7 38.1
Medicine 21.1 9.1 4.8
Neurology 13.2 9.1 31
Oncology 10.5 9.1 14.3
Surgery 2.6 - 2.4
Traumatology 5.3 - 9.5
0.247‡
Preexisting cardiac disease, in % 39.5 54.5 33.3 0.449‡
Psychiatric disorders, in %
Cognitive 10.5 9.1 19 0.537‡
Addictive 5.3 9.1 9.5 0.868‡
Psychotic – – – –
Affective 10.5 – 4.8 –
Other 5.3 – – –
DOS scores – initial 24 hours* 13.1
(0–9, 2.6)
13.3 (3–23, 6.2) 14.4 (1–33, 7.8) 0.699†
DOS scores – cumulative* 82.6
(2–30, 6.5)
46.2
(8–100, 28.3)
93.3
(10–485, 83.6)
0.198†
Pharmacological management with**
Haloperidol 0.8
(0.5–1, 0.3)
(0.5, –)
0.5
(0.5)
(–)
0.7
(0.5–1, 0.3)
(0.5, –)
0.513§
Pipamperone 434.7
(20–2520, 470.2)
(369.3, 268.8)
311.8
(160–620, 158.5)
(250, 270)
394
(40–1560, 292.7)
(280, 352.5)
0.839§
Lorazepam 5.5
(0.5–17, 3.9)
(5, 5)
3.6
(0.5–7, 3.4)
(3.5, 6.1)
7.7
(1–34, 4.3)
(4, 6.8)
0.647§
Remission of delirium in % 76.3 63.6 66.7 0.584‡
Day of remission** 6.1
(2–20, 4.7)
(4, 2.75)
3.9
(2–8, 1.8)
(5, –)
6.5
(2–20, 3.9)
(5.5, 4.3)
0.183†
DOS = Delirium Observation Screening scale * mean (range, standard deviation); ** mean (range, standard deviation) (median, interquartile range) † ANOVA; ‡ Pearson’s chi-
square; § Kruskal Wallis H-test
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Study strengths and limitations
Although this study had strengths – such as its relatively
large sample size, prospective data collection despite ret-
rospective analysis, structured approach, use of multiple
scales to detect and rate the severity of delirium, thrice dai-
ly DOS scores, and the examination of several different
psychotropic drugs, including lorazepam – limitations
must be noted. The design of the study was retrospective.
Although nursing staff were trained in the administration
of the DOS via a standardised training programme, inter-
rater reliability was not formally assessed. However, the
DOS has been accepted as a reliable scale and its ease of
use been documented [25, 26]. The allocation of medica-
tions was determined by the delirium management proto-
col, rather than randomised, and neither the patients nor
assessors were blinded to the medications being used. Fur-
ther, the number of patients managed with haloperidol or
atypical antipsychotics was lower.
Although these results provide first proof for the effective-
ness of pipamperone in the management of delirium, fur-
ther randomised controlled studies are required to confirm
these results.
Conclusions
Despite some methodological limitations, these initial re-
sults suggest that low-dose pipamperone, whether used
alone or as an adjunct to haloperidol, may be effective
in the management of delirium, irrespective of whether
the delirium is hypoactive, hyperactive, or mixed. Further-
more, pipamperone administered as an adjunct to haloperi-
dol may be benzodiazepine-sparing. The needs for ran-
domised studies notwithstanding, these results indicated
that pipamperone can be recommended as an effective
drug for the management of delirium.
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